Key Takeaways
- •The subcommittee reviewed 14 bills to address the illicit drug crisis, focusing on scheduling synthetic substances like xylazine and nitazenes while regulating equipment used for counterfeit pill production.
- •K. Fred Gingrich II (Executive Director, American Association of Bovine Practitioners) testified that xylazine is an indispensable veterinary tool, urging a balanced approach that preserves access for livestock treatment.
- •Rep. Griffith (R, VA-9) and Scott Oulton (President, INTR3PID Solutions LLC) discussed how wastewater testing provides a proactive early warning system for detecting emerging synthetic compounds before they cause fatalities.
- •Republicans prioritized criminalizing traffickers and closing scheduling gaps, while Rep. DeGette (D, CO-1) and other Democrats argued that cutting SAMHSA and Medicaid funding undermines public health-led recovery efforts.
- •These legislative efforts seek to modernize federal drug policy to match the speed of cartels that frequently alter chemical structures to evade current law and detection systems.
Read the full transcript
Starting at $350/mo
- Full hearing transcripts
- Speaker timestamps with video verification
- Organization & competitor mentions
- Same-day delivery
- Personalized summaries
30-day money-back guarantee on all paid plans.
Hearing Analysis
Overview
This hearing examined 14 legislative proposals designed to address the evolving crisis of illicit synthetic drugs, focusing on the emergence of substances like xylazine, nitazenes, and synthetic 7-OH ("gas station heroin"). The discussion centered on the tension between the need for rapid scheduling of new compounds to aid law enforcement and the potential unintended consequences for public health, research, and veterinary medicine. Lawmakers and witnesses also debated the impact of recent federal funding shifts and staffing reductions at public health agencies on the nation’s ability to sustain a recent decline in overdose deaths.
Key Testimony & Policy
Witnesses and members discussed a broad slate of bills aimed at closing regulatory loopholes exploited by transnational criminal organizations. A primary focus was H.R. 1266, the Combating Illicit Xylazine Act, which seeks to classify xylazine as a Schedule III substance. Dr. Fred Gingrich II, DVM, Executive Director of the American Association of Bovine Practitioners, testified that while illicit xylazine is a public health threat, the drug is an "indispensable tool" for sedating large animals. He argued that H.R. 1266 is superior to administrative scheduling by the Drug Enforcement Administration (DEA) because it includes statutory protections for legitimate veterinary use, preventing a "patchwork" of state regulations that could disrupt the cattle supply chain.
The hearing also addressed the proliferation of counterfeit pills. Mr. Scott Oulton, President of INTR3PID Solutions and former DEA forensics chief, highlighted the danger of illicit pill presses, noting that identical-looking pills often contain wildly different, lethal doses of fentanyl or nitazenes. He advocated for H.R. 5880, the Fight Illicit Pill Presses Act, which would require serialization of pill presses, and H.R. 7184, the PRESS Act, to criminalize the importation of precursor chemicals and manufacturing equipment. Oulton also promoted the "GUARD" method for forensic reporting and wastewater testing as critical early-warning systems to detect emerging threats before they appear in toxicology reports.
Public health experts raised concerns about the "whack-a-mole" nature of drug scheduling. Dr. Nabarun Dasgupta, PhD, MPH, of the University of North Carolina at Chapel Hill, warned that scheduling xylazine has already led to its replacement by medetomidine, a "fraternal twin" compound that can cause severe cardiac issues. He cautioned that H.R. 7970 (STOP Nitazenes Act) and H.R. 8000 (End 7-OH Act) might inadvertently hinder medical research or drive users toward even more dangerous analogs. Conversely, Sheriff Dennis Lemma of Seminole County, Florida, argued that scheduling is essential to provide law enforcement with the tools to hold traffickers accountable and deter the introduction of new synthetics.
Notable Exchanges & Partisan Dynamics
A sharp partisan divide emerged regarding the administration of federal health programs. Ranking Member Diana DeGette (D, CO-1) and Rep. Frank Pallone (D, NJ-6) criticized the Trump administration for what they characterized as "chaos" at the Substance Abuse and Mental Health Services Administration (SAMHSA). They highlighted the temporary cancellation of $2 billion in grant funding and significant staffing cuts, arguing these actions undermine the progress made in reducing overdose deaths. Dr. Yngvild Olsen, MD, MPH, former Director of the Center for Substance Abuse Treatment at SAMHSA, testified that these cuts, combined with proposed Medicaid work requirements and eligibility checks in the "Big Ugly Bill" (H.R. 1), could cause millions to lose access to medication-assisted treatment (MAT).
Republicans, led by Chairman Brett Guthrie (R, KY-2) and Rep. H. Griffith (R, VA-9), focused on the supply-side of the crisis. They defended the need for enhanced data collection on drug diversion through H.R. 5630 and argued that holding traffickers accountable is a necessary complement to treatment. Rep. John Joyce (R, PA-13) and Rep. Diana Harshbarger (R, TN-1) emphasized the importance of Tyler’s Law (H.R. 2004), which would require the Department of Health and Human Services (HHS) to study and issue guidance on fentanyl testing in emergency rooms, noting that current routine toxicology screens often miss the drug.
Organizations Mentioned
* Substance Abuse and Mental Health Services Administration (SAMHSA): Discussed extensively regarding recent funding instability, staffing cuts, and its role in administering the Substance Use Prevention, Treatment, and Recovery Services block grants. * Drug Enforcement Administration (DEA): Mentioned regarding its potential administrative scheduling of xylazine and its efforts to seize illicit pill presses and fentanyl in states like Kentucky. * Food and Drug Administration (FDA): Discussed in the context of H.R. 2715, which would grant the agency authority to destroy hazardous imported products at U.S. ports. * American Veterinary Medical Association (AVMA): Praised for its work on H.R. 1266 to ensure veterinarians maintain access to xylazine for large animal care. * University of North Carolina at Chapel Hill (UNC): Cited for its street drug checking program and research into the emergence of medetomidine as a xylazine replacement. * Centers for Medicare and Medicaid Services (CMS): Mentioned regarding its role in implementing Medicaid work requirements and its recent actions to withhold funding for peer recovery services in certain states. * World Health Organization (WHO): Referenced by Dr. Dasgupta regarding international drug scheduling protocols and the balance between medical utility and abuse potential.
What's Next
The subcommittee is expected to move toward a markup of the 14 bills discussed. Key points of negotiation will likely include the specific "carve-out" language for veterinary xylazine in H.R. 1266 and the reporting requirements for states in H.R. 5630. Democratic members indicated they would continue to press for oversight hearings regarding the staffing and funding levels at SAMHSA and the impact of Medicaid redeterminations on addiction treatment access.
Transcript
We are, we are just going to get through some openings, so the fact that all the witnesses aren't seated is fine at this moment. The subcommittee will come to order, and the chair recognizes himself for five minutes for an opening statement. In today's hearing, we will discuss 14 bills aimed at protecting Americans from illicit drug threats. Illicit drugs continue to pose a serious and evolving challenge to American safety and national security, fueling overdose deaths, increasing crime, and putting immense pressure on law enforcement and public health systems. So far this Congress, we have gotten strong policies across the finish line to crack down on the illicit drug crisis that we see across the country. However, there is still more to be done to protect our communities from these lethal substances. This is an issue that affects particularly Virginia and Appalachia, where we have unfortunately been impacted by the opioid epidemic. I hear countless stories across my district of individuals taking illicit drugs and mixing them with drugs we will be discussing today, like xylazine and fentanyl. Many of these illicit drugs are coming from illegal pill presses, often with ingredients coming from China. Our local law enforcement have been on the front lines battling this crisis, and this hearing will give us the opportunity to build on the work this subcommittee did in passing the HALT Fentanyl Act, led by myself and Mr. Latta, and Support for Patients and Communities Reauthorization Act, led by Chairman Guthrie. The President signed both of these pieces of legislation last year. We will examine H.R. 1266, Combating Illicit Xylazine Act, led by Representative Pfluger from Texas. This bill would classify xylazine as a Schedule III substance under the Controlled Substances Act, while also protecting its legitimate use in large animal veterinary medicine. This is extremely important for my district because, according to the National Cattlemen's Association, Virginia's 9th District is the largest cattle-producing congressional district east of the Mississippi. H.R. 5630, an important data collection issue that is championed by Representative Houchin from Indiana, would require enhanced data collection and reporting for opioid use disorder diversion data as part of the states' plan for their substance use prevention, treatment, and recovery services block grants. H.R. 2004, Tyler's Law, is led by Representative Latta from Ohio. The bill would require the Department of Health and Human Services to complete a study on how frequently hospitals test for fentanyl in patients experiencing an overdose and then use its results to issue guidance on implementing fentanyl testing in emergency rooms. Also introduced by Representative Latta is H.R. 7970, the Strengthening Tools to Outlaw Poisonous Stop Nitazenes Act, which would permanently schedule nitazenes as a Schedule I controlled substance. H.R. 8000, the End Needless Distribution of 7-OH Act, led by Representative Bilirakis from Florida, would regulate synthetic versions of 7-OH as a Schedule I controlled substance. The Preventing Rogue and Equipment for Synthetic Substances Press Act, H.R. 7184, introduced by Representative McDow from North Carolina, would criminalize the intentional importation of unlisted precursor chemicals and related equipment used to manufacture controlled substances. H.R. 8005, the Stop Pills That Kill Act, introduced by Representative Evans from Colorado, would implement new penalties and close a sentencing loophole for counterfeit pill production. Representative Hageman from Wyoming champions H.R. 5880, the Fight Illicit Pill Presses Act, which would add a serialization requirement for pill presses and punches. H.R. 1227, the Alternatives to Prevent Addiction in the Nation, or PAIN Act, led by Representative Miller-Meeks from Iowa and Representative Barragán from California, which I am also a cosponsor of, would expand access for seniors to non-opioid pain management options in Medicare Part D. H.R. 2715, the Destruction of Hazardous Imports Act, introduced by Representatives Higgins and Carter from Louisiana, would grant the FDA authority to destroy any FDA-regulated products that pose a significant risk to U.S. public health found at our ports. We will also be discussing other bills that deal with addressing this illicit drug issue, and while some of these bills may need further work, it is critical that we continue to look for ways to restrict access to lethal and dangerous substances in order to protect American lives, strengthen public safety, and prevent further harm to families and communities nationwide. I look forward to hearing from our witnesses and to the discussion. I now recognize the ranking member of the subcommittee, Ms. DeGette, for her five-minute opening statement.
Read the full transcript
Starting at $350/mo
- Full hearing transcripts
- Speaker timestamps with video verification
- Organization & competitor mentions
- Same-day delivery
- Personalized summaries
30-day money-back guarantee on all paid plans.
Not ready to subscribe?
Get a free daily digest with hearing summaries ranked by relevance.
Already have an account? Log in
